Diagnostic value of serum prostate-specific antigen in hemodialysis patients

International Journal of Urology

Volumn 10, Issue 5, 2003, Pages 247-250

  Sumura, Masahiro ^a,b   Yokogi, Hiroyuki ^a   Beppu, Masako ^a   Honda, Hiroshi ^a  

^a Matsue Seikyou General Hospital   (Japan)

^b Oki Hospital   (Japan)

Author keywords

Hemodialysis; Prostate cancer; Prostate specific antigen; PSA

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER SCREENING; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DIALYSIS; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; MALE GENITAL TRACT CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY; SERUM;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MASS SCREENING; MIDDLE AGED; PALPATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; RENAL DIALYSIS;

EID: 0037956031     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2003.00612.x     Document Type: Article

References (22)

1. Lindner A, Farewell VT, Sherrad DJ. High incidence of neoplasia in uremic patients receiving long term dialysis. Nephron. 1981; 27: 292-6.
2. Port FK, Ragheb NE, Schwartz AG et al. Neoplasms in dialysis patients: a population based study. Am. J. Kidney Dis. 1989; 14: 119-23.
3. Makita Y, Iwamoto T, Sagiyama K et al. Two cases of urogenital malignancies in male patients undergoing maintenance hemodialysis. Int. Urol. Nephrol. 1994; 26: 713-8.
4. Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-9.
5. Tzanakis I, Kazoulis S, Girousis N et al. Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron. 2002; 90: 230-3.
6. Djavan B, Shariat S, Ghawidel K et al. Impact on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology 1999; 53: 1169-74.
7. Wolff JM, Ting O, Borchers H et al. Serum level of prostate specific antigen in men on hemodialysis. Anticancer Res. 2000; 20: 5191-4.
8. Sasagawa I, Kubota Y, Hayami S et al. Serum level of total and free prostate specific antigen in men on hemodialysis. J. Urol. 1998; 160: 83-5.
9. Partin AW, Oesterling JE, Epstein JI et al. Influence of age and endocrine factors on Volume of benign prostate hyperplasia. J. Urol. 1991; 145: 405-9.
10. Kokot F, Weicek A, Schmidt-Gayk H et al. Influence of long-term erythropoietin therapy on endocrine abnormalities in haemodialyzed patients. Przegl. Lek. 1992; 49: 43-9.
11. Imai K, Kubota H. Mass screening for prostate cancer - How to eliminate clinically insignificant cancer. Jpn. J. Chemother. 1998; 25: 809-12.
12. Hayami S, Sasagawa I, Nakada T. Influence of sex hormones on prostate volume in men on hemodialysis. J. Androl. 2000; 21: 258-61.
13. Plascik TJ, Oesterling JE, Partin AL. Prostate-specific antigen: a decade of discovery - What we have learnt and where we are going? J. Urol. 1999; 162: 293-306.
14. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. JAMA 1993; 270: 860-4.
15. Catalona WJ, Smith DS, Ornstein DK et al. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5.
16. Lodding P, Aus G, Bergdahl S et al. Characteristics of screening detected prostate cancer in men 50-66 years old with 3-4 ng/mL prostate-specific antigen. J. Urol. 1998; 159: 899-903.
17. Babaian R, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA. The incidence of prostate cancer in a screening population to biopsy strategy. J. Urol. 2001; 165: 757-60.
18. Sasagawa I, Suzuki K, Ishizaki M et al. Prostate cancer in patients on long-term hemodialysis. Nephron. 1991; 59: 506-7.
19. Teruel JL, Cano T, Marcen R et al. Decrease in the haemoglobin level in hemodialysis patients undergoing antiandrogen therapy. Nephrol. Dial. Transplant. 1997; 12: 1262-3.
20. Chrisp P, Goa KL. Geserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions. Drugs 1991; 41: 254-88.
21. Nakata S, Inoue M, Takezawa Y, Kobayashi M, Kuribara H, Yamanaka H. Reduction rates of leuprorelin acetate concentration after hemodialysis in a case of prostate cancer associated with chronic renal failure. J. Jpn. Soc. Dial. Ther. 1998; 31: 1217-9.
22. Saruki K, Sekihara T, Mashimo M, Matuo H, Sekiguchi H. Leuproreline acetate blood levels and dialysance after the administration of sustained-release leuprorelin acetate in a dialysis case complicated by prostate cancer. Prostate 1998; 34: 191-4.